ASTRO Issues Guideline for Radiation Tx in Pancreatic Cancer
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings.
Pancreatic Cancer News
PANCREATIC CANCER ADVISOR
Pancreatic Cancer News
Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk
Risks for pancreatitis, pancreatic cancer higher in Korean patients with newly diagnosed T2DM.
Early Closure of Phase 2 Trial on Checkpoint Inhibitors in Metastatic PDAC Due to Missed Efficacy End Point
Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.
Higher Fasting Plasma Glucose May Up Pancreatic Cancer Risk
Continuous increase in risk of pancreatic cancer with elevating fasting glucose, even within normal range.
Novel Test Accurately Identifies Precancerous Pancreatic Cysts
Cyst classifier test is based on clinical and imaging features, genetic and biochemical markers.
Phase 3 Study Evaluating Novel Therapy for Pancreatic Cancer Discontinued
Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.
ASCO Guideline Update: Modified FOLFIRINOX Is Preferred as Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma
The rate of grade 3/4 adverse events was higher for patients with resected pancreatic adenocarcinoma treated with adjuvant mFOLFIRINOX versus gemcitabine.
Maintenance Olaparib May Delay Progression of BRCA-Related Pancreatic Cancer
The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.
Cancer Consultation Low in Noncurable Pancreatic Adenocarcinoma
Many patients with noncurable pancreatic adenocarcinoma do not have a specialized cancer consultation and most do not receive cancer-directed therapy.
FFPE Tissue Specimens Deemed Adequate for Molecular Studies: NCI-SEER
Regions of tumor and normal tissue on FFPE tissue specimens obtained from the NCI SEER-linked Virtual Tissue Repository were annotated by a pathologist.
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial
Olaparib maintenance therapy improved PFS in patients with metastatic pancreatic adenocarcinoma characterized by a deleterious BRCA1/2 mutation.
The Incidence of Some Obesity-Related Cancers Is Increasing Among Young Adults
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Study results suggest a new combination regimen could become the standard of care for some patients.
Phase 1, 2 Trials to Assess Imaging System for Gastrointestinal Cancer Detection
Researchers are seeking to assess the initial safety and efficacy of LUM015 imaging of colorectal, pancreatic, and esophageal cancers using the LUM 2.6 imaging device.
Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer
Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.
Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer
The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.
Pancreatic Tumor Bacteria Found To Be Similar to Microbes Located in the Mouth
The bacterial strains found in oral samples may be representative of the types of strains that exist in the tumor microbiomes of patients with pancreatic or GI disease.
Preclinical Data Suggest BET Plus PARP Inhibition May Treat Pancreatic Cancer
Preclinical data suggest that a BET inhibitor plus a PARP inhibitor may be a promising new approach to treat pancreatic cancer.
Pancreatic Cancer Risk Linked to Number of First-Degree Relatives Who Are Affected by Cancer
Pancreatic risk rises in a dose-response manner with increasing number of affected first-degree relatives.
KRAS Mutations May Influence Location, Local Recurrence of Resected Pancreatic Cancer
Different KRAS mutations may be associated with differing primary tumor locations and patterns of local recurrence in resected pancreatic cancer.
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
